Antipodean Pharmaceuticals has initiated a Phase II clinical trial to test its lead compound mitoquinone (MitoQ) for the treatment of Parkinson’s disease in New Zealand and Australia.

MitoQ, based on a novel technology, targets lipophilic cations that transport and concentrate antioxidants into the mitochondria where they accumulate up to a thousandfold.

Patients who meet the diagnosis of Parkinson’s disease but are yet to receive any treatment to relieve its symptoms will be included in the trial, the company said.

The trial will involve ten consultant neurologists at New Zealand and Australia’s main regional hospitals, who will assess and advise potential participants.